Cargando…
Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications
Umbilical Cord blood is an intuitively attractive stem cell source, but its use has declined since it is associated with an increased procedure-related morbidity and transplant related mortality. Some of this reflects that cord blood transplants are more often HLA-mismatched compared to other unrela...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020792/ https://www.ncbi.nlm.nih.gov/pubmed/35465327 http://dx.doi.org/10.3389/fcell.2022.836594 |
_version_ | 1784689641937436672 |
---|---|
author | Wynn, Rob Nataraj, Ramya Nadaf, Rubiya Poulton, Kay Logan, Alison |
author_facet | Wynn, Rob Nataraj, Ramya Nadaf, Rubiya Poulton, Kay Logan, Alison |
author_sort | Wynn, Rob |
collection | PubMed |
description | Umbilical Cord blood is an intuitively attractive stem cell source, but its use has declined since it is associated with an increased procedure-related morbidity and transplant related mortality. Some of this reflects that cord blood transplants are more often HLA-mismatched compared to other unrelated donor transplants. The ability to transplant in such a setting, indeed without high rates of chronic Graft versus Host Disease (GVHD), constitutes an advantage compared to other unrelated donor cell sources and there are other advantages specifically associated with cord blood as a donor cell source. These advantages must be weighed against its disadvantage, and we have utilised cord blood preferentially as a donor cell source in certain clinical situations in paediatric medicine. In non-malignant diseases, outcomes in metabolic disease are critically dependent on age at transplant and the enzyme delivered by that transplant, and in cord blood transplantation then the time to transplant can be minimised and the engrafted recipients have higher chimerism that delivers higher enzyme levels. In malignant diseases, studies have described reduced relapse rate and better GVHD-free survival, and so we have prioritised cord as a donor cell source where the risk of relapse is highest, and the effects of higher transplant related mortality is most clearly offset by the reduced relapse rates. |
format | Online Article Text |
id | pubmed-9020792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90207922022-04-21 Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications Wynn, Rob Nataraj, Ramya Nadaf, Rubiya Poulton, Kay Logan, Alison Front Cell Dev Biol Cell and Developmental Biology Umbilical Cord blood is an intuitively attractive stem cell source, but its use has declined since it is associated with an increased procedure-related morbidity and transplant related mortality. Some of this reflects that cord blood transplants are more often HLA-mismatched compared to other unrelated donor transplants. The ability to transplant in such a setting, indeed without high rates of chronic Graft versus Host Disease (GVHD), constitutes an advantage compared to other unrelated donor cell sources and there are other advantages specifically associated with cord blood as a donor cell source. These advantages must be weighed against its disadvantage, and we have utilised cord blood preferentially as a donor cell source in certain clinical situations in paediatric medicine. In non-malignant diseases, outcomes in metabolic disease are critically dependent on age at transplant and the enzyme delivered by that transplant, and in cord blood transplantation then the time to transplant can be minimised and the engrafted recipients have higher chimerism that delivers higher enzyme levels. In malignant diseases, studies have described reduced relapse rate and better GVHD-free survival, and so we have prioritised cord as a donor cell source where the risk of relapse is highest, and the effects of higher transplant related mortality is most clearly offset by the reduced relapse rates. Frontiers Media S.A. 2022-04-06 /pmc/articles/PMC9020792/ /pubmed/35465327 http://dx.doi.org/10.3389/fcell.2022.836594 Text en Copyright © 2022 Wynn, Nataraj, Nadaf, Poulton and Logan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Wynn, Rob Nataraj, Ramya Nadaf, Rubiya Poulton, Kay Logan, Alison Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications |
title | Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications |
title_full | Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications |
title_fullStr | Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications |
title_full_unstemmed | Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications |
title_short | Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications |
title_sort | strategies for success with umbilical cord haematopoietic stem cell transplantation in children with malignant and non-malignant disease indications |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020792/ https://www.ncbi.nlm.nih.gov/pubmed/35465327 http://dx.doi.org/10.3389/fcell.2022.836594 |
work_keys_str_mv | AT wynnrob strategiesforsuccesswithumbilicalcordhaematopoieticstemcelltransplantationinchildrenwithmalignantandnonmalignantdiseaseindications AT natarajramya strategiesforsuccesswithumbilicalcordhaematopoieticstemcelltransplantationinchildrenwithmalignantandnonmalignantdiseaseindications AT nadafrubiya strategiesforsuccesswithumbilicalcordhaematopoieticstemcelltransplantationinchildrenwithmalignantandnonmalignantdiseaseindications AT poultonkay strategiesforsuccesswithumbilicalcordhaematopoieticstemcelltransplantationinchildrenwithmalignantandnonmalignantdiseaseindications AT loganalison strategiesforsuccesswithumbilicalcordhaematopoieticstemcelltransplantationinchildrenwithmalignantandnonmalignantdiseaseindications |